All monoclonal antibody (mAb) therapies are in limited supply, and not everyone will be eligible for treatment. A prescription from a healthcare provider is required to receive any mAb therapy. Variants, like Omicron, may have an impact on the effectiveness of mAb therapies. Due to the high frequency of the Omicron variant, three mAb therapies are not currently authorized in any U.S. region: REGEN-COV (casirivimab and imdevimab), bamlanivimab and etesevimab, and sotrovimab (currently not authorized by FDA).
There are two mAb therapies that are authorized for use in the U.S. through EUA and expected to be effective against the Omicron variant. Bebtelovimab may be used during a COVID-19 infection. Evusheld (tixagevimab and cilgavimab) may be used before exposure to help prevent infection.
People who are interested in receiving the treatment can reach out to a healthcare provider or call Indiana 211 (866-211-9966) to learn more. Click here for a map of mAb therapy providers and additional information about COVID-19 treatment.